Left atrial appendage occlusion for stroke prevention in atrial fibrillation in Europe: results of the European Heart Rhythm Association survey

被引：31

作者：

Lip, Gregory Y. H. ^{[1
]}

Dagres, Nikolaos ^{[2
]}

Proclemer, Alessandro ^{[3
]}

Svendsen, Jesper Hastrup ^{[4
,5
]}

Pison, Laurent ^{[6
]}

Blomstrom-Lundqvist, Carina ^{[7
]}

机构：

[1] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp Birmingham, Birmingham B15 2TT, W Midlands, England

[2] Univ Athens, Cardiol Dept 2, Attikon Univ Hosp, Athens, Greece

[3] Univ Hosp S Maria della Misericordia, Dept Cardiothorac Sci, Udine, Italy

[4] Univ Copenhagen, Dept Cardiol, Ctr Heart, Rigshosp, DK-1168 Copenhagen, Denmark

[5] Univ Copenhagen, Danish Natl Res Fdn Ctr Cardiac Arrhythmia, DK-1168 Copenhagen, Denmark

[6] Maastricht Univ, Dept Cardiol, Med Ctr, Maastricht, Netherlands

[7] Uppsala Univ, Dept Cardiol, Inst Med Sci, Uppsala, Sweden

来源：

EUROPACE | 2013年 / 15卷 / 01期

关键词：

Anticoagulation; Atrial fibrillation; Left atrial appendage occlusion; Stroke;

D O I：

10.1093/europace/eus413

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The purpose of this EP wire survey was to assess clinical practice in relation to the use of left atrial appendage occlusion (LAAO) devices for stroke prevention in atrial fibrillation (AF) among members of the European Heart Rhythm Association research network. The average number of performed LAAO was 10.6 per year and most (73) centres performed 10 procedures per year. We found that LAAO was being performed for stroke prevention in AF, for the most common indication being othe patient has absolute contraindication to long term oral anticoagulants'. Among survey respondents, LAAO procedures are most often performed by interventional cardiologists. Experience varied widely, and this was reflected in the wide range of thromboembolic and procedural (tamponade, bleeding) complications reported by the respondents to this EP wire survey.

引用

页码：141 / 143

页数：3

共 13 条

[1] What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
Ahrens, Ingo
Lip, Gregory Y. H.
Peter, Karlheinz
[J]. THROMBOSIS AND HAEMOSTASIS, 2011, 105 (04) : 574 - 578
[2] Camm AJ, 2012, EUROPACE, V14, P1385, DOI [10.1093/eurheartj/ehs253, 10.1093/europace/eus305]
[3] Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study
Friberg, Leif
Rosenqvist, Marten
Lip, Gregory Y. H.
[J]. EUROPEAN HEART JOURNAL, 2012, 33 (12) : 1500 - +
[4] Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
Holmes, David R.
Reddy, Vivek Y.
Turi, Zoltan G.
Doshi, Shephal K.
Sievert, Horst
Buchbinder, Maurice
Mullin, Christopher M.
Sick, Peter
[J]. LANCET, 2009, 374 (9689) : 534 - 542
[5] Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice
Huisman, Menno V.
Lip, Gregory Y. H.
Diener, Hans-Christoph
Brueckmann, Martina
van Ryn, Joanne
Clemens, Andreas
[J]. THROMBOSIS AND HAEMOSTASIS, 2012, 107 (05) : 838 - 847
[6] Kaul S, 2010, J AM COLL CARDIOL, V55
[7] Landmesser U, 2011, EUR HEART J
[8] OPINION The role of aspirin for stroke prevention in atrial fibrillation
Lip, Gregory Y. H.
[J]. NATURE REVIEWS CARDIOLOGY, 2011, 8 (10) : 602 - 606
[9] National-Institute-for-Health-and-Clinical-Excellence, 2010, INT PROC GUID, P349
[10] O'Riordan M, 2010, WATCHMAN DELAYED FDA

← 1 2 →